2022
DOI: 10.1002/rai2.12060
|View full text |Cite
|
Sign up to set email alerts
|

Immunophenotyping identifies distinct cellular signatures for systemic lupus erythematosus and lupus nephritis

Abstract: Background: Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease characterized by development of autoantibodies and multiorgan involvement. Kidney involvement, termed lupus nephritis, has major impact on life expectancy. It is increasingly recognized that SLE is likely a common clinical manifestation of pathophysiologically diverse processes, and lupus nephritis has similarly been associated with several distinct immunological processes. We compared the immune cell phenotypes of individu… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 54 publications
0
1
0
Order By: Relevance
“…Оригінальні наукові роботи Original Papers out nephritis and healthy donors. So SLE patients with and without LN have distinct immunologic differences that may reflect the unique pathophysiological processes contributing to disease manifestations [1]. LN may present with clinical manifestations (arterial hypertension, edema) [4] and/or laboratory changes (proteinuria, active urinary sediment, increased serum creatinine), and can progress to end-stage renal disease (ESRD) [3].…”
mentioning
confidence: 99%
“…Оригінальні наукові роботи Original Papers out nephritis and healthy donors. So SLE patients with and without LN have distinct immunologic differences that may reflect the unique pathophysiological processes contributing to disease manifestations [1]. LN may present with clinical manifestations (arterial hypertension, edema) [4] and/or laboratory changes (proteinuria, active urinary sediment, increased serum creatinine), and can progress to end-stage renal disease (ESRD) [3].…”
mentioning
confidence: 99%